11 results
DEF 14A
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Definitive proxy
7:15am
community and business strategy development. Prior to joining Allergan, she served as Executive Director and Senior Healthcare Analyst at J.P. Morgan … to community property laws where applicable.
Name of Beneficial Owner
Number of Shares Beneficially Owned
Percentage of Shares Beneficially Owned
5
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
22 Dec 23
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
9:04am
of lorundrostat, we have been pleased to see accumulating evidence generated by the medical community highlighting aldosterone as a key driver
8-K
MLYS
Mineralys Therapeutics Inc
14 Sep 23
Departure of Directors or Certain Officers
4:11pm
of Global Investor Relations and Strategy, leading engagement with the investment community and business strategy development. Prior to joining Allergan
DRS/A
MLYS
Mineralys Therapeutics Inc
29 Dec 22
Draft registration statement (amended)
12:00am
, if approved, by patients, the medical community and third-party payors.
If we are unable to develop, receive marketing approval for and successfully … of market acceptance of such product candidates by healthcare providers, product recipients, healthcare payors and others in the medical community
DRS/A
1e9xleu9k0u dl4vrb
7 Dec 22
Draft registration statement (amended)
12:00am
DRS
ujy143mo2i4726
4 Nov 22
Draft registration statement
12:00am
DRS
EX-10.9
wm26rvvejzb9jmhy
4 Nov 22
Draft registration statement
12:00am
DRS
EX-10.5
85gwj4 lt3itv
4 Nov 22
Draft registration statement
12:00am
DRS
EX-10.7
v2tned rl1h
4 Nov 22
Draft registration statement
12:00am
DRS
EX-10.6
vqqh9wf4 u95
4 Nov 22
Draft registration statement
12:00am
- Prev
- 1
- Next